Patents by Inventor KIM M. VAN VLIET
KIM M. VAN VLIET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240109938Abstract: Provided herein are modified recombinant adeno-associated virus (rAAV) capsid proteins, such as modified rAAV1, rAAV5, and rAAV6 capsid proteins, rAAV particles comprising such capsid proteins, nucleic acid molecules encoding such capsid proteins, as well as compositions, kits and methods of use thereof.Type: ApplicationFiled: February 6, 2023Publication date: April 4, 2024Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventors: George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna, Arun Srivastava
-
Publication number: 20230136849Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.Type: ApplicationFiled: September 1, 2022Publication date: May 4, 2023Applicant: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, George Vladimirovich Aslanidi, Sergei Zolotukhin, Mavis Agbandje-McKenna, Kim M. Van Vliet, Li Zhong, Lakshmanan Govindasamy
-
Publication number: 20230129762Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.Type: ApplicationFiled: July 5, 2022Publication date: April 27, 2023Applicant: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna
-
Patent number: 11434260Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.Type: GrantFiled: February 22, 2019Date of Patent: September 6, 2022Assignee: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna
-
Patent number: 11124544Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.Type: GrantFiled: August 8, 2017Date of Patent: September 21, 2021Assignee: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna
-
Publication number: 20210269487Abstract: Provided herein are modified recombinant adeno-associated virus (rAAV) capsid proteins, such as modified rAAV1, rAAV5, and rAAV6 capsid proteins, rAAV particles comprising such capsid proteins, nucleic acid molecules encoding such capsid proteins, as well as compositions, kits and methods of use thereof.Type: ApplicationFiled: February 12, 2021Publication date: September 2, 2021Applicant: University of Florida Research Foundation, IncorporatedInventors: George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna, Arun Srivastava
-
Publication number: 20210253644Abstract: Disclosed are next-generation multi-mutated capside protein-modified rAAV expression vector, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using these high transduction efficiency vector constructs in a variety of therapeutic applications including, inter alia, as delivery agents for the treatment or amelioration of one or more diseases or abnormal conditions in an affected mammal using in vivo and/or ex situ viral vector-based gene therapy protocols. Also disclosed are large-scale production methods for the multi-mutated, capsid-modified rAAV expression vector, viral particles, and infectious virions, as well as use of the disclosed compositions in the manufacture of medicaments for use in a variety of in vitro and/or in vivo therapeutic methodologies.Type: ApplicationFiled: December 23, 2020Publication date: August 19, 2021Applicant: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, Li Zhong, Sergei Zolotukhin, George Vladimirovich Aslanidi, Mavis Agbandje-McKenna, Kim M. Van Vliet, Chen Ling
-
Patent number: 10934327Abstract: Disclosed are next-generation multi-mutated capsid protein-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using these high transduction efficiency vector constructs in a variety of therapeutic applications including, inter alia, as delivery agents for the treatment or amelioration of one or more diseases or abnormal conditions in an affected mammal using in vivo and/or ex situ viral vector-based gene therapy protocols. Also disclosed are large-scale production methods for the multi-mutated, capsid-modified rAAV expression vectors, viral particles, and infectious virions, as well as use of the disclosed compositions in the manufacture of medicaments for use in a variety of in vitro and/or in vivo therapeutic methodologies.Type: GrantFiled: November 28, 2017Date of Patent: March 2, 2021Assignee: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, Li Zhong, Sergei Zolotukhin, George Vladimirovich Aslanidi, Mavis Agbandje-McKenna, Kim M. Van Vliet, Chen Ling
-
Patent number: 10927150Abstract: Provided herein are modified recombinant adeno-associated virus (rAAV) capsid proteins, such as modified rAAV1, rAAV5, and rAAV6 capsid proteins, rAAV particles comprising such capsid proteins, nucleic acid molecules encoding such capsid proteins, as well as compositions, kits and methods of use thereof.Type: GrantFiled: September 9, 2019Date of Patent: February 23, 2021Assignee: University of Florida Research Foundation, IncorporatedInventors: George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna, Arun Srivastava
-
Patent number: 10815279Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.Type: GrantFiled: May 24, 2018Date of Patent: October 27, 2020Assignee: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, George Vladimirovich Aslanidi, Sergei Zolotukhin, Mavis Agbandje-McKenna, Kim M. Van Vliet, Li Zhong, Lakshmanan Govindasamy
-
Publication number: 20200010510Abstract: Provided herein are modified recombinant adeno-associated virus (rAAV) capsid proteins, such as modified rAAV1, rAAV5, and rAAV6 capsid proteins, rAAV particles comprising such capsid proteins, nucleic acid molecules encoding such capsid proteins, as well as compositions, kits and methods of use thereof.Type: ApplicationFiled: September 9, 2019Publication date: January 9, 2020Applicant: University of Florida Research Foundation, IncorporatedInventors: George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna, Arun Srivastava
-
Publication number: 20190284244Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.Type: ApplicationFiled: February 22, 2019Publication date: September 19, 2019Applicant: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna
-
Patent number: 10294281Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.Type: GrantFiled: February 27, 2017Date of Patent: May 21, 2019Assignee: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna
-
Publication number: 20190127424Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.Type: ApplicationFiled: November 2, 2018Publication date: May 2, 2019Applicant: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, George Vladimirovich Aslanidi, Sergei Zolotukhin, Mavis Agbandje-McKenna, Kim M. Van Vliet, Li Zhong, Lakshmanan Govindasamy
-
Publication number: 20190016759Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.Type: ApplicationFiled: May 24, 2018Publication date: January 17, 2019Applicant: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, George Vladimirovich Aslanidi, Sergei Zolotukhin, Mavis Agbandje-McKenna, Kim M. Van Vliet, Li Zhong, Lakshmanan Govindasamy
-
Publication number: 20180223312Abstract: Disclosed are next-generation multi-mutated capsid protein-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using these high transduction efficiency vector constructs in a variety of therapeutic applications including, inter alia, as delivery agents for the treatment or amelioration of one or more diseases or abnormal conditions in an affected mammal using in vivo and/or ex situ viral vector-based gene therapy protocols. Also disclosed are large-scale production methods for the multi-mutated, capsid-modified rAAV expression vectors, viral particles, and infectious virions, as well as use of the disclosed compositions in the manufacture of medicaments for use in a variety of in vitro and/or in vivo therapeutic methodologies.Type: ApplicationFiled: November 28, 2017Publication date: August 9, 2018Applicant: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, Li Zhong, Sergei Zolotukhin, George Vladimirovich Aslanidi, Mavis Agbandje-McKenna, Kim M. Van Vliet, Chen Ling
-
Patent number: 10011640Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.Type: GrantFiled: March 14, 2014Date of Patent: July 3, 2018Assignee: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, George Vladimirovich Aslanidi, Sergei Zolotukhin, Mavis Agbandje-McKenna, Kim M. Van Vliet, Li Zhong, Lakshmanan Govindasamy
-
Publication number: 20180105559Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.Type: ApplicationFiled: August 8, 2017Publication date: April 19, 2018Applicant: University of Florida Research Foundation, Inc.Inventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna
-
Publication number: 20180030096Abstract: Provided herein are modified recombinant adeno-associated virus (rAAV) capsid proteins, such as modified rAAV1, rAAV5, and rAAV6 capsid proteins, rAAV particles comprising such capsid proteins, nucleic acid molecules encoding such capsid proteins, as well as compositions, kits and methods of use thereof.Type: ApplicationFiled: February 3, 2016Publication date: February 1, 2018Applicant: University of Florida Research Foundation, Inc.Inventors: George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna, Arun Srivastava
-
Publication number: 20170275337Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.Type: ApplicationFiled: February 27, 2017Publication date: September 28, 2017Applicant: University of Florida Research Foundation, Inc.Inventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna